Skip to main content

Table 2 Summary of findings table: 21 excluded from meta-analysis shown by italics at first author's name

From: Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

#

First author

Year

Pilot

Power calc.

ITT sample

PP sample

PP sample > median (62.5)

Attrition rate %

Original ITT analysis

‘Main’ outcome identified

Nature of ‘main’ outcome

End-point

A42

Aabel

2001

N

N

51

51

N

0.0

N

Daily symptom score (VAS)

Continuous

10 days

A43

Aabel

2000

N

Y

70

66

Y

5.7

N

Daily symptom score

Continuous

32 days

A44

Aabel

2000

N

Y

80

73

Y

8.8

N

Daily symptom score (VAS)

Continuous

10 days

A47

Baker

2003

N

Y

?

44

N

?

N

Revised Test Anxiety (RTA) scale

Continuous

4 days

A48

bBalzarini

2000

N

N

66

61

N

7.6

N

Index of Total Severity during Recovery (re: skin colour, temp, oedema, pigmentation)

Continuous

7–8 weeks

A49

bBeer

1999

N

N

40

40

N

0.0

Y

Time between to regular uterine contractions

Continuous

7 h or induction of labour

A50

Belon

2006

N

N

43

43

N

0.0

N

Reversal in expression of antinuclear antibody titre

Dichotomous

1 month

A51

Belon

2007

Y

N

39

25

N

35.9

N

Blood arsenic concentration

Continuous

2 months

A52

bBergmann (a)

2000

N

Y

?

37

N

?

N

Cycle normalisation

Dichotomous

3 months or 3 cycles

A52

bBergmann (b)

2000

N

Y

?

30

N

?

Y

Cycle normalisation

Dichotomous

3 months or 3 cycles

A53

Bernstein

2006

N

N

200

171

Y

14.5

N

Psoriasis Area Severity Index

Continuous

12 weeks

A55

Berrebi

2001

N

N

71

71

Y

0.0

N

Mammary pain (VAS)

Continuous

4 days

A56

Bignamini

1987

N

N

34

32

N

5.9

N

(Systolic) Blood pressure

Continuous

4 weeks

A59

bCialdella

2001

N

Y

96

61

N

36.5

Y

“Success rate” for clinical global impression

Dichotomous

30 days

A60

Clark

2000

Y

N

18

14

N

22.2

N

Daily pain (100 mm VAS)

Continuous

14 days

A272

Colau

2012

N

Y

108

101

Y

6.5

Y

Hot flash score

Continuous

12 weeks

A61

Cornu

2010

Y

Y

92

92

Y

0.0

Y

Cumulated blood loss at drain removal

Continuous

Up to 7 d

A62

bDiefenbach

1997

N

N

258

209

Y

19.0

Y

Treatment success (‘very good’ + ‘good’ results) – physician-assessed

Dichotomous

Up to 3 weeks

A63

bErnst

1990

N

N

122 a

122 a

N

0.0

N

Venous filling time

Continuous

24 days

A64

bFerley

1989

N

N

478

462

Y

3.3

N

Proportion of patients recovered (from 5 cardinal symptoms and from temp > 37.5)

Dichotomous

By 48 h

A67

Frass

2005

N

N

55

50

N

9.1

N

Total volume of tracheal secretions per day

Continuous

2 days

A68

bFreitas

1995

N

N

86

69

Y

19.8

N

Score of intensity, frequency and duration of symptoms

Continuous

6 months

A69

Friese

2007

N

N

144

68

Y

52.8

Y

Sinusitis symptoms score

Continuous

21 days

A70

bFriese

1997

N

Y

97

82

Y

15.5

N

Frequency of non-adenoidectomy (imputed)

Dichotomous

3 months

A74

Gerhard (a)

1998

N

Y

38

28

N

26.3

N

Frequency of pregnancy

Dichotomous

3 months

A74

Gerhard (b)

1998

N

Y

27

21

N

22.2

N

Frequency of pregnancy

Dichotomous

3 months

A74

Gerhard (c)

1998

N

Y

31

17

N

45.2

N

Frequency of pregnancy

Dichotomous

3 months

A75

GRECHO

1989

N

Y

300

300

Y

0.0

N

Number of hours from operation until first stool

Continuous

Up to c.100 h

A274

Harrison

2013

Y

N

34

28

N

17.6

N

Sleep onset latency

Continuous

28 days

A76

Hart

1997

N

N

93

73

Y

21.5

N

Frequency of improved pain score (VAS)

Dichotomous

Duration of 5 days

A78

Hitzenberger

2005

N

Y

?

?

-

?

N

Blood pressure

Continuous

6 weeks

A79

bHofmeyr

1990

Y

N

162

161

Y

0.6

N

Daily questionnaire responses: those without moderate/severe perineal pain

Dichotomous

4 days

A80

Jacobs

2006

N

N

292

265

Y

9.2

Y

Duration of diarrhoea

Continuous

Up to 7 days

A81

Jacobs

2007

Y

N

60

58

N

1.7

N

No. of days until no pain or fever for at least two consecutive days

Continuous

Up to 1 weeks

A83

bKaziro

1984

N

N

77

77

Y

0.0

N

Pain score (VAS): Numbers without moderate/severe pain (imputed)

Dichotomous

8 days

A84

Khuda-Bukhsh

2005

Y

N

55

55

N

0.0

N

Urine arsenic concentration (imputed)

Continuous

11 days

A85

Khuda-Bukhsh

2011

Y

N

28

14

N

50.0

N

Urine arsenic concentration

Continuous

2 months

A86

Kim

2005

Y

Y

40

34

N

15.0

Y

Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ total symptoms)

Continuous

4 weeks

A88

Kolia-Adam

2008

N

N

30

30

N

0.0

N

Hours of sleep per night

Continuous

8 weeks

A89

Kotlus

2010

N

N

60

57

N

5.0

N

Area of ecchymosis

Continuous

7 days

A91

Labrecque

1992

N

Y

174

162

Y

6.9

N

Proportion of pts with healed warts (physician assessment)

Dichotomous

18 weeks

A92

bLeaman

1989

N

N

34

34

N

0.0

N

Pain (0-10 VAS) - area-under-the-curve

Continuous

6 h

A93

Lewith

2002

N

N

242

202

Y

16.5

Y

Asthma VAS (imputed)

Continuous

16 weeks

A94

Lipman

1999

N

N

101

90

Y

10.9

N

Average snoring score computed from responses to Snore Diary over last 5 nights of 10

Continuous

Duration of 10 days

A293

Malapane

2014

Y

N

30

30

N

0.0

N

Tonsillitis pain score (Wong-Baker FACES)

Continuous

6 days

A95

McCutcheon

1996

N

N

77

58

N

24.7

N

State Anxiety score

Continuous

Duration of 15 days

A275

Naidoo

2013

Y

N

30

30

N

0.0

N

Wheal diameter

Continuous

4 weeks

A100

Oberbaum

2001

N

N

32

30

N

6.3

Y

Area-under-the-curve score for stomatitis symptoms (severity and duration) (imputed)

Continuous

14 days minimum

A101

bOberbaum

2005

Y

N

45

40

N

11.1

Y

Venous haemoglobin

Continuous

72 h postpartum

A103

Padilha

2011

N

N

131

120

Y

8.4

Y

Proportion of workers with Pb decrease of at least 25% (imputed)

Dichotomous

30 days

A104

bPapp

1998

N

N

372

334

Y

10.2

N

Proportion of patients with physician-assessed recovery in health (i.e. ‘no symptoms’)

Dichotomous

By 48 h

A105

Paris

2008

N

Y

131

105

Y

19.8

Y

Proportion patients with cumulated consumption of morphine < 10 mg/day (imputed)

Dichotomous

24 h post-op

A108

bRahlfs

1976

Y

Y

?

63

Y

?

N

Improvement of irritable bowel syndrome (scale 1 + 2)

Dichotomous

14 days

A109

bRahlfs

1978

Y

N

119

85

Y

28.6

N

Improvement of irritable bowel syndrome (scale 3 + 4)

Dichotomous

15 days

A277

Razlog

2012

Y

N

20

18

N

10.0

N

Conner’s PSQ (‘Impulsivity and/or hyperactivity’ category)

Continuous

3 weeks

A111

bReilly

1986

N

Y

158

109

Y

31.6

N

Propn. with improvement in daily overall VAS score (imputed)

Dichotomous

5 weeks

A112

bReilly

1994

N

Y

28

24

N

14.3

Y

Propn. with improvement in daily overall VAS score

Dichotomous

4 weeks

A113

Robertson

2007

N

Y

190

111

Y

41.6

N

Tonsillectomy pain (VAS) score

Continuous

14 days

A116

Schmidt

2002

N

Y

208

194

Y

6.7

Y

Reduction of body weight

Continuous

3 days

A117

Seeley

2006

N

N

29

26

N

10.3

N

Area of ecchymosis

Continuous

10 days

A278

Sencer

2012

N

Y

195

106

Y

45.6

N

Sum of Walsh scores for mucositis

Continuous

Up to 20 days post-transplant

A120

Singer

2010

N

Y

80

79

Y

1.3

Y

Area-under-the-curve pain score

Continuous

14 days

A122

Stevinson

2003

Y

N

64

62

N

3.1

Y

Pain (Short Form McGill Pain Questionnaire

Continuous

14 days

A123

bTaylor

2000

N

Y

51

50

N

2.0

Y

Daily overall VAS score (imputed)

Continuous

3–4 weeks

A125

Tveiten

1991

N

N

44

36

N

18.2

N

Muscle soreness (VAS) (imputed)

Continuous

3 days

A126

bTveiten

1998

N

N

?

46

N

?

N

Muscle soreness (VAS)

Continuous

3 days

A128

bVickers

1998

N

Y

?

400

Y

?

Y

Muscle soreness (VAS)

Continuous

2 days

A130

Weiser

1994

N

Y

173

155

Y

10.4

N

Sinusitis score

Continuous

5 months or on relapse

A131

bWiesenauer

1985

N

N

106

74

Y

30.2

N

Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’

Dichotomous

4 weeks

A132

Wiesenauer

1989

N

N

221

152

Y

31.2

N

Sinusitis score

Continuous

3–4 weeks

A133

bWiesenauer

1990

N

N

243

171

Y

29.6

N

Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’

Dichotomous

Approx 5 weeks

A134

Wiesenauer

1991

N

N

176

106

Y

39.8

N

Treatment success

Dichotomous

12 weeks

A135

bWiesenauer

1995

N

N

132

120

Y

9.1

N

Symptom relief (nasal): ‘Symptom-free’ + ‘Obvious relief’

Dichotomous

4 weeks

A136

Wolf

2003

Y

N

60

59

N

1.7

N

Haematoma area

Continuous

2 weeks

A137

Zabolotnyi

2007

N

Y

113

113

Y

5.3

Y

Sinusitis severity score cf. Day 0 (imputed)

Continuous

7 days

  1. ITT intention to treat, PP per protocol, Y yes, N no
  2. aSample size refers to number of legs, not the number of subjects, in the trial
  3. bIncluded in meta-analysis by Shang et al. [http://www.ispm.unibe.ch/unibe/portal/fak_medizin/ber_vkhum/inst_smp/content/e93945/e93964/e180045/e180897/1433.Study_characteristics_of_homoeopathy_studies_corrected_eng.pdf (accessed 1 July 2016)]